issue. The use of these expensive techniques in either routine practice or only in case of steady state collection failure remains unanswered.
The novel cyclin-dependent kinase inhibitor dinaciclib (SCH727965) promotes apoptosis and abrogates microenvironmental cytokine protection in chronic lymphocytic leukemia cells Chronic lymphocytic leukemia (CLL) represents the most prevalent type of adult leukemia and is currently incurable with available therapies. The introduction of fludarabine, fludarabine/cyclophosphamide and either of these combined with rituximab has improved the outcome for younger patients with CLL. Treatment options available for patients in the setting of relapsed disease following receipt of chemoimmunotherapy are less where most patients have high-risk genomic findings including IgV H un-mutated disease, del(17p13.1) and del(11q22.3) associated with poor treatment response (reviewed in Grever et al.
1
). Identifying therapies with novel mechanisms of action for this patient group is important.
One class of drugs that has promise for the treatment of relapsed CLL is the cyclin-dependent kinases (CDK) inhibitors. Flavopiridol is the first member of this group to be extensively tested based upon pre-clinical work by several groups, [2] [3] [4] which, although having a narrow therapeutic window, was shown to be clinically active in high-risk genomic patients with a dose-limiting Accepted article preview online 30 May 2012; advance online publication, 13 July 2012 side effect of hyper-acute tumor lysis syndrome. 5, 6 A multicenter phase II trial confirmed the activity of flavopiridol, including in patients with del(17p13.1), but also toxicity associated with its narrow therapeutic index (American Society of Hematology Annual meeting 2010). These results provide support for development of CDK inhibitors that have an improved therapeutic index.
Dinaciclib (SCH 727965) 7 is a selective inhibitor of CDK 1, 2 and 9 (IC50 of o5 nM) that was selected pre-clinically by an in vivo screen that identified it as having a favorable therapeutic index of maximally-tolerated dose to effective dose in an ovarian carcinoma xenograft mouse model. Specifically, the therapeutic index of dinaciclib was 10 versus 2 for BMS-387032 (now known as SNS-032) and o1 for flavopiridol. 8 Dinaciclib has completed phase I testing in solid tumors where the dose-limiting side effect of neutropenia and cytokine-release syndrome was observed with a relatively favorable therapeutic index (that is, no diarrhea and less Previous studies have shown that stromal protection is mediated by the phosphatidylinositol 3-kinase (PI3-kinase) p110-alpha isoform 9 -mediated pathway, which is supported by Figure 2f , where the pan-PI3-kinase inhibitor LY294002 and the p110-alpha isoform-specific inhibitor PIK-75 can be seen to in fact abrogate the protective effect of stromal attachment toward dinaciclib. In contrast, the p110-delta-specific inhibitor and the p110-betaspecific inhibitors of PI3-kinase cannot (Supplemental Figure 1) . Herein, we have described that the pan-CDK inhibitor dinaciclib has potent pre-clinical in vitro activity against CLL cells independently of high-risk genomic features. We also have demonstrated that dinaciclib downregulates mRNA and protein expression of the important anti-apoptotic protein MCL-1 independently of caspases, which has been shown to be essential for CLL cell Figures 2A and B) . 10 Although MCL-1 modulation may serve as a pharmacodynamic marker of CDK inhibition, as we have shown with flavopiridol previously, it was not demonstrated to correlate with response, suggesting that alternative mechanisms are relevant. 11 In this regard we demonstrate that dinaciclib, similar to flavopiridol, abrogates the protective anti-apoptotic effect of several microenvironment cytokines, including CD40L, BAFF and IL-4. However, treatment of CLL cells with dinaciclib followed by incubation on stromal cell or fibronectin co-culture protects from dinaciclib-mediated cytotoxicity. Of great interest, treatment of CLL cells with a p110-alpha-specific PI3-kinase inhibitor, but not p110-beta or delta inhibitors, abrogates this effect. Collectively this points to rational combination strategies of dinaciclib with pan-PI3 kinase inhibitors in CLL to enhance the cytotoxic potential of this agent.
survival (Supplemental
Based on these promising pre-clinical data and also a favorable therapeutic index observed in pre-clinical and solid tumor studies, a phase I disease-specific study of dinaciclib has been initiated in relapsed and refractory CLL. A preliminary report of this study has þ cells from CLL patients were pre-treated with or without 1 mM dinaciclib in suspension for 2 h and then incubated in suspension or on an HS-5 cell layer for 24 h. Viability was measured at 24 h by annexin V/propidium iodide staining and flow cytometry. (e) CD19 þ cells from CLL patients were incubated for 2 h with or without 1 mM dinaciclib in suspension or on a fibronectin-coated plate. Viability was measured at 24 h by annexin V/propidium iodide staining and flow cytometry. (f ) CD19 þ cells from CLL patients were pre-treated with or without 1 mM dinaciclib in suspension for 2 h and then incubated in suspension or on an HS-5 cell layer for 24 h with or without 25 mM LY294002 or 35 nM PIK-75. Viability was measured at 24 h by annexin V/propidium iodide staining and flow cytometry.
